Ovarian cancer

Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis

Y. Y. Shi, Jiang, H., Shi, Y. Y., and Jiang, H., “Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis”, vol. 15, p. -, 2016.

This meta-analysis study aimed to investigate the correlation between CD44-positive cancer stem cells (CSCs) and clinicopathological features and its effect on the survival of ovarian cancer patients. A comprehensive literature search in the electronic databases, including PubMed, EMBASE, and Wanfang (up to December 1, 2015), was conducted. Publications assessing the clinical or prognostic significance of CD44 expression in ovarian cancer were identified and reviewed until December 1, 2015.

miR-146a and miR-196a2 polymorphisms in ovarian cancer risk

X. C. Sun, Zhang, A. C., Tong, L. L., Wang, K., Wang, X., Sun, Z. Q., Zhang, H. Y., Sun, X. C., Zhang, A. C., Tong, L. L., Wang, K., Wang, X., Sun, Z. Q., and Zhang, H. Y., “miR-146a and miR-196a2 polymorphisms in ovarian cancer risk”, vol. 15, p. -, 2016.

We investigated the relationship between miR-146a and miR-196a2 genetic polymorphisms and development of ovarian cancer in a Chinese population. A total of 134 patients and 227 control subjects were involved in our study between January 2012 and October 2014 from China-Japan Union Hospital of Jilin University. Genotyping of miR-146a and miR-196a2 was accomplished by polymerase chain reaction coupled with restriction fragment length polymorphism analysis.